Literature DB >> 22455286

Cardiac arrhythmias and left ventricular hypertrophy in systemic hypertension.

Riffat Sultana1, Nuzhat Sultana, Abdul Rashid, Syed Zahid Rasheed, Mansoor Ahmed, Muhammad Ishaq, Abdus Samad.   

Abstract

BACKGROUND: Hypertensive left ventricular hypertrophy (LVH) is associated with increased risk of arrhythmias and mortality. Objective was to investigate the prevalence of cardiac arrhythmias and LVH in systemic hypertension.
METHODS: In all subjects blood pressure was measured, electrocardiography and echocardiography was done. Holter monitoring and exercise test perform in certain cases. There were 500 hypertensive patients, 156 (31.2%) men and 344 (69%) women > 30 years of age in the study. Among them 177 (35.4%) were diabetic, 224 (45%) were dyslipidemia, 188 (37.6%) were smokers, and 14 (3%) had homocysteinemia. Duration of hypertension (HTN) was > or = 2 years). Mean systolic BP (SBP) was 180 +/- 20 mm Hg and diastolic BP (DBP) was 95 +/- 12 in male and female patients. Left ventricular mass index (LVMI) was 119.2 +/- 30 gm/m2 in male while 103 +/- 22 gm/m2 in female patients. Palpitation was seen in 126 (25%) male and 299 (59.8%) female patients. Atrial fibrillation was noted in 108 (21.6%) male and 125 (25%) female patients, 30 (6%) male and 82 (16.4%) female patients had atrial flutter. Ventricular tachycardia was noted in 37 (7.4%) male and 59 (11.8%) female patients. Holter monitoring showed significant premature ventricular contractions (PVC'S) in 109 (21.8%) male and 128 (25.69%) female patients while Holter showed atrial arrhythmias (APC'S) in 89 (17.8%) males and 119 (23.8%) females. Angiography findings diagnosed coronary artery disease in 119 (23.8%) with CAD male and 225 (45%) without CAD while 47 (9.4%) females presented with CAD and 109 (21.8%) without CAD.
CONCLUSION: A significant association has been demonstrated between hypertension and arrhythmias. Diastolic dysfunction of the left ventricle, left atrial size and function, as well as LVH have been suggested as the underlying risk factors for supraventricular, ventricular arrhythmias and sudden death in hypertensives with LVH.

Entities:  

Mesh:

Year:  2010        PMID: 22455286

Source DB:  PubMed          Journal:  J Ayub Med Coll Abbottabad        ISSN: 1025-9589


  5 in total

1.  Risk factor paradox: No prognostic impact of arterial hypertension and smoking in patients with ventricular tachyarrhythmias.

Authors:  Kathrin Weidner; Michael Behnes; Jonas Rusnak; Gabriel Taton; Tobias Schupp; Linda Reiser; Armin Bollow; Thomas Reichelt; Dominik Ellguth; Niko Engelke; Philip Kuche; Jorge Hoppner; Ibrahim El-Battrawy; Siegfried Lang; Christoph A Nienaber; Kambis Mashayekhi; Dennis Ferdinand; Christel Weiß; Martin Borggrefe; Ibrahim Akin
Journal:  Cardiol J       Date:  2018-12-19       Impact factor: 2.737

Review 2.  Approach to Management of Premature Ventricular Contractions.

Authors:  Michael P O'Quinn; Anthony J Mazzella; Prabhat Kumar
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-09-05

3.  Heart rate variability and arrhythmic patterns of 24-hour Holter electrocardiography among Nigerians with cardiovascular diseases.

Authors:  Rasaaq Ayodele Adebayo; Amanze Nkemjika Ikwu; Michael Olabode Balogun; Anthony Olubunmi Akintomide; Olufemi Eyitayo Ajayi; Victor Oladeji Adeyeye; Tuoyo Omasan Mene-Afejuku; Olaniyi James Bamikole; Suraj Adefabi Ogunyemi; Adeola Olubunmi Ajibare; Omolola Abiodun Oketona
Journal:  Vasc Health Risk Manag       Date:  2015-06-29

4.  The Diagnostic Value of Combined 24-h BP and ECG Holter Monitoring in Detection of Cardiac Arrhythmias in Patients with Arterial Hypertension.

Authors:  Nabil Naser; Esad Pepic; Sevleta Avdic
Journal:  Acta Inform Med       Date:  2022-03

5.  Prevalence and determinants of cardiac arrhythmias and conduction anomalies in adults aged ≥ 40 years in Jimma Town, Southwest of Ethiopia: a cross-sectional study.

Authors:  Iyasu Tadesse Bukata; Elsa Tegene; Teshome Gobena; Yohannes Markos Woldesenbet
Journal:  Afr Health Sci       Date:  2022-03       Impact factor: 1.108

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.